Various CDK inhibitors are already FDA-approved for treatment of different types of metastatic cancers and CDK4/6 inhibition has been shown to inhibit tumor growth of medulloblastoma cells in vivo42,43. This evidence concerns the gene CDK4 and metastatic malignant neoplasm.